Novartis Stock

Novartis P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Novartis (NOVN.SW) as of Aug 14, 2026 is 18.96. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was 21.58 — a change of -12.15% (lower).

P/CF

18.96

YoY

-12.15%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Novartis is 2026 18.96 . P/CF (Price-to-Cash-Flow Ratio) of Novartis was 2025 21.58 . It decreases by -12.15% lower compared to the previous year.
Access this data via the Eulerpool API

Novartis Stock analysis

What does Novartis do? Novartis AG is a globally active company operating in the pharmaceutical, ophthalmology, and generics manufacturing sectors. The company, headquartered in Basel, Switzerland, was founded in 1996 and originated from a merger between Ciba-Geigy and Sandoz. Novartis AG is now a leading company worldwide in the research, development, production, and marketing of pharmaceuticals and other health products. Novartis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novartis stock

P/CF (Price-to-Cash-Flow Ratio) of Novartis is 18.96 in 2026.

P/CF (Price-to-Cash-Flow Ratio) of Novartis changed from 21.58 to 18.96, representing a -12.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Novartis since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Novartis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Novartis

All Key Metrics — Novartis